Effects of a ritonavir‐containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjects

• Published in: Pharmacology research & perspectives Vol. 10; no. 6; pp. e01024 - n/a
• Main Authors: Zha, Jiuhong, Jiang, Qi, Yao, Betty B., Cohen, Daniel E., Carter, David C., Menon, Rajeev M.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.12.2022; Wiley
• Subjects: Abscesses; Adult; Antiretroviral drugs; Antiviral Agents; Antiviral drugs; Confidence intervals; Cross-Over Studies; CYP3A inhibitor; dasabuvir; Disease prevention; Drug dosages; Drug Interactions; everolimus; Everolimus - pharmacokinetics; Healthy Volunteers; Hepatitis C; Humans; Inhibitor drugs; Ligands; ombitasvir; paritaprevir; Pharmacokinetics; Pharmacology; ritonavir; Ritonavir - pharmacology; Severe acute respiratory syndrome coronavirus 2; sirolimus; Sirolimus - pharmacokinetics; Standard deviation; everolimus; ombitasvir; hepatitis C; ritonavir; sirolimus; CYP3A inhibitor; dasabuvir; paritaprevir

The immunosuppressive agents sirolimus and everolimus are sensitive CYP3A4 substrates with narrow therapeutic index. Ritonavir is a strong CYP3A inhibitor. A phase 1 study was conducted to evaluate the pharmacokinetics, safety, and tolerability of the co‐administration of sirolimus or everolimus wit...